862 related articles for article (PubMed ID: 27224994)
1. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
[TBL] [Abstract][Full Text] [Related]
2. Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database.
Bushe C; Sobanski E; Coghill D; Berggren L; De Bruyckere K; Leppämäki S
CNS Drugs; 2016 Apr; 30(4):317-34. PubMed ID: 27055440
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
Lee SI; Song DH; Shin DW; Kim JH; Lee YS; Hwang JW; Park TW; Yook KH; Lee JI; Bahn GH; Hirata Y; Goto T; Takita Y; Takahashi M; Lee S; Treuer T
Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
5. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA.
Brod M; Adler LA; Lipsius S; Tanaka Y; Heinloth AN; Upadhyaya H
Atten Defic Hyperact Disord; 2015 Jun; 7(2):141-50. PubMed ID: 25563210
[TBL] [Abstract][Full Text] [Related]
6. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials.
Asherson P; Bushe C; Saylor K; Tanaka Y; Deberdt W; Upadhyaya H
J Psychopharmacol; 2014 Sep; 28(9):837-46. PubMed ID: 25035246
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
Wietecha LA; Clemow DB; Buchanan AS; Young JL; Sarkis EH; Findling RL
CNS Neurosci Ther; 2016 Jul; 22(7):546-57. PubMed ID: 26922462
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
Wietecha L; Williams D; Shaywitz S; Shaywitz B; Hooper SR; Wigal SB; Dunn D; McBurnett K
J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL).
Matza LS; Johnston JA; Faries DE; Malley KG; Brod M
Qual Life Res; 2007 Nov; 16(9):1511-20. PubMed ID: 17874207
[TBL] [Abstract][Full Text] [Related]
11. Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine.
Thome J; Dittmann RW; Greenhill LL; Lipsius S; Tanaka Y; Bushe C; Escobar R; Heinloth AN; Upadhyaya H
Atten Defic Hyperact Disord; 2017 Dec; 9(4):219-229. PubMed ID: 28477289
[TBL] [Abstract][Full Text] [Related]
12. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
Walker DJ; Mason O; Clemow DB; Day KA
Postgrad Med; 2015; 127(7):686-701. PubMed ID: 26343377
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
Simpson D; Plosker GL
CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
Simpson D; Plosker GL
Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
[TBL] [Abstract][Full Text] [Related]
15. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
[TBL] [Abstract][Full Text] [Related]
16. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study.
Adler L; Tanaka Y; Williams D; Trzepacz PT; Goto T; Allen AJ; Escobar R; Upadhyaya HP
J Clin Psychopharmacol; 2014 Aug; 34(4):461-6. PubMed ID: 24977716
[TBL] [Abstract][Full Text] [Related]
17. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.
Buitelaar JK; Casas M; Philipsen A; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; van Oene JC; Schäuble B
Psychol Med; 2012 Jan; 42(1):195-204. PubMed ID: 21733214
[TBL] [Abstract][Full Text] [Related]
18. Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate.
Rösler M; Ginsberg Y; Arngrim T; Adamou M; Niemelä A; Dejonkheere J; van Oene J; Schäuble B
World J Biol Psychiatry; 2013 May; 14(4):282-90. PubMed ID: 21517701
[TBL] [Abstract][Full Text] [Related]
19. Assessment of effects of atomoxetine in adult patients with ADHD: consistency among three geographic regions in a response maintenance study.
Tanaka Y; Escobar R; Upadhyaya HP
Atten Defic Hyperact Disord; 2017 Jun; 9(2):113-120. PubMed ID: 28058589
[TBL] [Abstract][Full Text] [Related]
20. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
Takahashi M; Goto T; Takita Y; Chung SK; Wang Y; Gau SS
Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]